Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 2
1973 4
1974 1
1975 1
1976 1
1977 4
1978 4
1979 4
1980 1
1981 1
1982 3
1983 3
1984 4
1986 2
1987 2
1988 3
1989 4
1991 2
1992 2
1994 1
1995 2
1996 1
1997 3
1999 2
2000 1
2002 4
2004 6
2005 6
2006 2
2007 9
2008 8
2009 6
2010 3
2011 7
2012 2
2013 8
2014 5
2015 2
2016 2
2017 5
2018 2
2019 8
2020 7
2021 4
2022 4
2023 2
2024 6
2025 7
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

173 results

Results by year

Filters applied: . Clear all
Page 1
Desonide.
[No authors listed] [No authors listed] 2021 Jan 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Jan 18. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000795 Free Books & Documents. Review.
Desonide has not been studied during breastfeeding. Since only extensive application of the most potent corticosteroids may cause systemic effects in the mother, it is unlikely that short-term application of topical corticosteroids would pose a risk to the breastfed infant …
Desonide has not been studied during breastfeeding. Since only extensive application of the most potent corticosteroids may cause sys …
Hijacking ERAD for targeted degradation of transmembrane proteins.
Song H, Wang W, Mei T, Zheng H, Ning K, Liu X, Cheung S, Cao Z, Sheng D, Mai X, Zhu H, Guo G, Liu S, Wei R, Wang Q, Cao Y, Ding Y, Fei Y, Liu R, Hattori M, Sheng C, Lu B. Song H, et al. Cell. 2026 Mar 19;189(6):1768-1784.e24. doi: 10.1016/j.cell.2026.01.018. Cell. 2026. PMID: 41861782
Here, we established a TPD technology hijacking ERAD and named it ERAD-engaging chimeras (ERADECs), capable of degrading TM targets with high efficacy. We identified desonide as a binder of SYVN1, an ER E3 ligase mediating ERAD. We designed ERADECs targeting programmed dea …
Here, we established a TPD technology hijacking ERAD and named it ERAD-engaging chimeras (ERADECs), capable of degrading TM targets with hig …
Desonide foam: a review.
Parish D, Scheinfeld N. Parish D, et al. Drugs Today (Barc). 2008 Jan;44(1):55-62. doi: 10.1358/dot.2008.44.1.1143847. Drugs Today (Barc). 2008. PMID: 18301804 Review.
Desonide foam is a newly approved topical corticosteroid preparation of 0.05% desonide. ...Given the favorable safety profile of all other desonide preparations and their utility as a low potency corticosteroid, desonide foam promises to be a useful ad …
Desonide foam is a newly approved topical corticosteroid preparation of 0.05% desonide. ...Given the favorable safety profile …
Overview on desonide 0.05%: a clinical safety profile.
Wong VK, Fuchs B, Lebwohl M. Wong VK, et al. J Drugs Dermatol. 2004 Jul-Aug;3(4):393-7. J Drugs Dermatol. 2004. PMID: 15303783 Review.
Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses. ...A pharmacovigilance program, initiated in 1992 for all countries where desonide is available, collected reports of adverse events associated …
Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses. ...A pharma …
Desonide: a review of formulations, efficacy and safety.
Kahanek N, Gelbard C, Hebert A. Kahanek N, et al. Expert Opin Investig Drugs. 2008 Jul;17(7):1097-104. doi: 10.1517/13543784.17.7.1097. Expert Opin Investig Drugs. 2008. PMID: 18549345 Review.
BACKGROUND: Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive dermatoses. ...OBJECTIVE: This article provides a review of desonide's history, pharmacodynamic properties, vehicle technology, efficac …
BACKGROUND: Desonide is a low-potency topical corticosteroid that has been used for decades in the treatment of steroid-responsive de …
A Review of Topical Corticosteroid Foams.
Payne J, Habet KA, Pona A, Feldman SR. Payne J, et al. J Drugs Dermatol. 2019 Aug 1;18(8):756-770. J Drugs Dermatol. 2019. PMID: 31424707 Review.
METHODS: A literature review was conducted using the keywords "clobetasol," "betamethasone," "propionate," "valerate," "topical," "foam," "vehicles," "desonide," and "clinical trial." Thirty-seven articles were chosen. RESULTS: For moderate plaque-type psoriasis, 68% of su …
METHODS: A literature review was conducted using the keywords "clobetasol," "betamethasone," "propionate," "valerate," "topical," "foam," "v …
Drugs for atopic dermatitis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Jun 15;62(1600):89-96. Med Lett Drugs Ther. 2020. PMID: 32555122 No abstract available.
Desonide foam 0.05%: safety in children as young as 3 months.
Hebert AA; Desonide Foam Phase III Clinical Study Group. Hebert AA, et al. J Am Acad Dermatol. 2008 Aug;59(2):334-40. doi: 10.1016/j.jaad.2008.04.019. J Am Acad Dermatol. 2008. PMID: 18638631 Clinical Trial.
BACKGROUND: Desonide 0.05% was recently developed in an emulsion foam formulation. OBJECTIVE: The safety of desonide foam 0.05% in children aged 3 months to 17 years was evaluated in two phase II studies and one phase III study. ...LIMITATIONS: The studies evaluated …
BACKGROUND: Desonide 0.05% was recently developed in an emulsion foam formulation. OBJECTIVE: The safety of desonide foam 0.05 …
Tega-dermabrasion.
O'Connor JJ Jr, Vasudevan A. O'Connor JJ Jr, et al. Anesthesiology. 2007 Sep;107(3):515. doi: 10.1097/01.anes.0000278863.84694.34. Anesthesiology. 2007. PMID: 17721261 No abstract available.
Seborrheic dermatitis.
Scheinfeld NS. Scheinfeld NS. Skinmed. 2005 Jan-Feb;4(1):49-50. doi: 10.1111/j.1540-9740.2005.03961.x. Skinmed. 2005. PMID: 15654167 No abstract available.
173 results